Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexza Submits NDA For Staccato Loxapine
Alexza Pharmaceuticals (Alexza) has submitted its New Drug Application (NDA) for Staccato loxapine (AZ-004) to the FDA. AZ-004 is an inhalation product candidate being developed for the rapid
Alexza Pharmaceuticals (Alexza) has submitted its New Drug Application (NDA) for Staccato loxapine (AZ-004) to the FDA. AZ-004 is an inhalation product candidate being developed for the rapid
Arid Pharmaceuticals has presented updated clinical data from its Phase 2 study evaluating oral Ridaforolimus in combination with Trastuzumab (Herceptin) in patients with resistant, metastatic breast cancer. As
Celsion has completed the enrollment and treatment of the first patient in China, as part of Phase III ThermoDox Heat trial for the treatment of hepatocellular carcinoma (HCC).
ImmunoGen has presented positive clinical data on trastuzumab-DM1 (T-DM1), at the 32nd Annual San Antonio Breast Cancer Symposium. T-DM1 comprises ImmunoGen’s DM1 cancer-cell killing agent linked to the
bioTheranostics has reported findings from three studies using the company’s breast cancer molecular test. Data from the studies were presented at the CTRC-AACR San Antonio Breast Cancer Symposium
Roche’s Stage, a Phase III trial evaluating Ocrelizumab as a treatment for seropositive rheumatoid arthritis (RA) patients with a previous inadequate response to methotrexate (MTX), met its primary
Amcor has appointed Ralf Wunderlich, former MD of Linpac Packaging as the new head of its Asia-Pacific flexibles business. The company will there after concentrate on acquisition of
BP Petronas Acetyls Sdn Bhd (BPPA) has announced its plans to increase its acetic acid production from Paka plant to 600,000 tonnes annually from next the year, reported
India-based IOL chemicals and Pharmaceuticals (IOLCP) has initiated the manufacturing operations at its new plant of isobutyl benzene(IBB) having annual capacity of 6600 MT to ensure ready availability
Vivakor has entered into an exclusive, $5m license agreement with consumer product specialist, Regeneca International. The agreement exclusively licenses to Regeneca distribution rights to a new nutraceutical formulation